From Name

From Email

To Name

To Email

Message

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

from TCTMD

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort TCTMD There is no evidence that paclitaxel-coated devices used for the treatment of femoropopliteal artery disease increases the long-term risk of death when compared with an uncoated balloon or stent, according to a large analysis of Medicare Advantage patients. READ MORE

more